Brainstorm Cell Therapeutics Files Definitive Proxy Statement

TL;DR

Brainstorm Cell Therapeutics DEF 14A is out - shareholders vote on directors & auditors soon.

AI Summary

Brainstorm Cell Therapeutics Inc. filed its definitive proxy statement on August 16, 2024, for its annual meeting of stockholders. The filing provides details regarding the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.

Why It Matters

This filing is crucial for shareholders as it outlines the company's leadership, compensation structures, and the key decisions they will vote on, impacting the company's future direction.

Risk Assessment

Risk Level: medium — DEF 14A filings are routine disclosures, but the specific proposals and company performance discussed within can carry inherent risks for investors.

Key Players & Entities

• BRAINSTORM CELL THERAPEUTICS INC. (company) — Registrant
• 0001104659-24-090303.txt (document) — Filing document name
• 20240816 (date) — Filing date
• 20240916 (date) — Period of report

FAQ

Key Financial Figures

• $0.00005 — 1 shares of the Company's common stock, $0.00005 par value per share (the "Common Stock"

Filing Documents

• tm2420696-3_def14a.htm (DEF 14A) — 782KB
• bc_netloss-4c.jpg (GRAPHIC) — 54KB
• bc_returntsr-4c.jpg (GRAPHIC) — 59KB
• px_24brainstormproxy1pg01-bw.jpg (GRAPHIC) — 367KB
• px_24brainstormproxy1pg02-4c.jpg (GRAPHIC) — 177KB
• 0001104659-24-090303.txt ( ) — 1657KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management The following table sets forth certain information as of July 31, 2024 with respect to the beneficial ownership of our Common Stock by the following: (i) each of our current directors; (ii) the officers who served as President and Chief Executive Officer, Co-Chief Executive Officer, President and Chief Medical Officer and Interim Chief Financial Officer in fiscal year 2023 (the "Named Executive Officers"); and (iii) all of our current executive officers and directors as a group. As of July 31, 2024, to the knowledge of the Company, no shareholder of the Company beneficially owns more than five percent (5)% of the outstanding shares of our Common Stock. For purposes of the following table, beneficial ownership is determined in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as otherwise noted in the footnotes to the table, we believe that each person or entity named in the table has sole voting and investment power with respect to all shares of our Common Stock shown as beneficially owned by that person or entity (or shares such power with his or her spouse). Under the SEC's rules, shares of our Common Stock issuable under options that are exercisable on or within 60 days after July 31, 2024 ("Presently Exercisable Options") or under warrants that are exercisable on or within 60 days after July 31, 2024 ("Presently Exercisable Warrants") are deemed outstanding and therefore included in the number of shares reported as beneficially owned by a person or entity named in the table and are used to 7 compute the percentage of the Common Stock beneficially owned by that person or entity. These shares are not, however, deemed outstanding for computing the percentage of the Common Stock beneficially owned by any other person or entity. Unless otherwise indicated, the address of each person listed in the table is c/

View Full Filing

View this DEF 14A filing on SEC EDGAR